Seven Eight Capital’s TherapeuticsMD TXMD Stock Holding History

Seven Eight Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-254	Closed	-$79K	–	708
2018 Q2	$79K	Buy	+254	New	+$77.6K	0.01%	446

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Seven Eight Capital's TXMD Position: Q3 2018 in Review

Seven Eight Capital sold out of TherapeuticsMD (TXMD) in Q3 2018, closing a stake of 254 shares — an estimated $79K sold.

Seven Eight Capital first reported a position in TXMD in Q2 2018 and held it in 1 quarter. The position peaked at $79K in Q2 2018. 155 funds tracked by Wall St. Rank hold TXMD as of Q3 2018.

Seven Eight Capital reported no remaining TherapeuticsMD position as of Q3 2018 after selling out during the quarter.
Seven Eight Capital sold 254 TherapeuticsMD shares in Q3 2018, an estimated $79K.
Seven Eight Capital first reported a position in TherapeuticsMD in Q2 2018 and held it in 1 quarter.
Seven Eight Capital's TherapeuticsMD position peaked at $79K in Q2 2018.
155 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2018.

Based on Seven Eight Capital's 13F filing for Q3 2018, filed 18 Oct 2018.